The hemostatic properties of thawed pooled cryoprecipitate up to 72 hours

Transfusion

Volumn 56, Issue 6, 2016, Pages 1356-1361

  Green, Laura ^a   Backholer, Lucy ^b   Wiltshire, Mike ^b   Platton, Sean ^a   Stanworth, Simon J ^b   Cardigan, Rebecca ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; BLOOD GROUP ANTIGEN; HEMOSTATIC AGENT;

ARTICLE; CRYOPRECIPITATE; ENVIRONMENTAL TEMPERATURE; HEMATOLOGICAL PROCEDURE; HEMOSTASIS; ROTATIONAL THROMBOELASTOMETRY; SHELF LIFE; THAWING; THROMBIN TIME; BLOOD CLOTTING TEST; BLOOD STORAGE; BLOOD TRANSFUSION; CRYOPRESERVATION; HUMAN; PROCEDURES; STANDARDS; TEMPERATURE; THROMBOELASTOGRAPHY; TIME FACTOR;

BLOOD COAGULATION TESTS; BLOOD GROUP ANTIGENS; BLOOD PRESERVATION; BLOOD TRANSFUSION; CRYOPRESERVATION; FACTOR VIII; FIBRINOGEN; HEMOSTATICS; HUMANS; TEMPERATURE; THROMBELASTOGRAPHY; TIME FACTORS;

EID: 84973161375     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13571     Document Type: Article

References (24)

1. Guidelines for the blood transfusion services in the UK. 8th ed. Section 7.18. London: The Stationery Office; 2013.
2. Tinegate H, Allard S, Grant-Casey J, et al., Cryoprecipitate for transfusion: which patients receive it and why? A study of patterns of use across three regions in England. Transfus Med 2012; 22: 356-61.
3. Bennett E, Dormandy K., Pool's cryoprecipitate and exhausted plasma in the treatment of von Willebrand's disease and factor-XI deficiency. Lancet 1966; 2: 731-2.
4. Barrett KE, Israëls MC, Burn AM., The effect of cryoprecipitate concentrate in patients with classical haemophilia. Lancet 1967; 1: 191-2.
5. O'Shaughnessy DF, Atterbury C, Bolton MP, et al., Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
6. Circular of information for the use of human blood and blood components [Internet]. Ottawa (ON): Canadian Blood Services; 2005 [cited 2015 Oct 11]. Available from: https://www.blood.ca/en/hospitals/circular-information.
7. Shakur H, Roberts I, Bautista R, et al., Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
8. Holcomb JB, Tilley BC, Baraniuk S, et al., Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313: 471-82.
9. Rourke C, Curry N, Khan S, et al., Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012; 10: 1342-51.
10. Stanworth S, Davenport R, Curry N, et al., Mortality from trauma haemorrhage and opportunities for improvement in transfusion practice. Br J Surg 2016; 130: 357-65.
11. Green L, Knight M, Seeney F, et al., The haematological features and transfusion management of women who required massive transfusion for major obstetric haemorrhage in the UK: a population based study. Br J Haematol 2016; 172: 616-24.
12. Curry N, Rourke C, Davenport R, et al., Early cryoprecipitate for major haemorrhage in trauma: a randomised controlled feasibility trial. Br J Anaesth 2015; 115: 76-83.
13. The 'Red Book'. Guidelines for the blood transfusion services in the United Kingdom. 8th ed. London: The Stationery Office; 2013.
14. Hunt BJ, Allard S, Keeling D, et al., A practical guideline for the haematological management of major haemorrhage. Br J Haematol 2015; 170: 788-803.
15. Lawrie AS, Green L, Mackie IJ, et al., Factor XIII-an under diagnosed deficiency-are we using the right assays? J Thromb Haemost 2010; 8: 2478-82.
16. Lang T, Bauters A, Braun SL, et al., Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005; 16: 301-10.
17. Hemker HC, Giesen P, Al Dieri R, et al., Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
18. AABB Standards Program Committee. Standards for blood banks and transfusion services. Bethesda: AABB; 2013.
19. Spivey MA, Jeter EK, Lazarchick J, et al., Postfiltration factor VIII and fibrinogen levels in cryoprecipitate stored at room temperature and at 1 to 6 degrees C. Transfusion 1992; 32: 340-3.
20. Korte WC, Szadkowski C, Gähler A, et al., Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110: 239-45.
21. Shenkman B, Einav Y, Livnat T, et al., In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. Blood Transfus 2014; 12: 78-84.
22. Dardik R, Loscalzo J, Inbal A., Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006; 4: 19-25.
23. Lawrie AS, Harrison P, Cardigan RA, et al., The characterization and impact of microparticles on haemostasis within fresh-frozen plasma. Vox Sang 2008; 95: 197-204.
24. Sheffield WP, Bhakta V, Jenkins C., Stability of coagulation protein activities in single units or pools of cryoprecipitate during storage at 20-24°C for up to 24 h. Vox Sang 2016; 110: 12-9.